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Is there an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers?
A population-based case-control study It is unknown if SSRIs has a direct ulcerogenic effect. The aim of this study was to investigate if there is a possible association between use of SSRIs and uncomplicated peptic ulcers (UPU).
Methods: A population based case-control study was conducted in the county of Funen, Denmark, using local prescription database and patient register. The 4862 cases all had a first diagnosis of UPU from 1995 to 2009. Controls (n=19448), matched for age and sex, were selected by risk-set sampling.
Results: The adjusted odds ratio (OR) of UPU among current, recent, and past users of SSRIs were 1.50 (95% CI 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 have found an interaction between concurrent use of non-steroidal antiinflammatory drug (NSAID) and SSRI. 1, 2, 4, 6, 9, 12 The pharmacological mechanism underlying this adverse effect is thought to depend on the release of serotonin in platelets, which is important for their aggregation process. 14 Platelets are unable to synthesize serotonin, but can acquire it from the circulation by serotonin transporters. 15 SSRIs inhibit these transporters and will lower the level of serotonin inside the platelets after a short duration of treatment. 16 It is unknown if processes other than the anti-thrombocytic effect might be involved in the SSRI-induced UGB, and it is unknown if SSRIs has a direct ulcerogenic effect. We undertook this case-control study to assess a possible association between SSRIs and uncomplicated peptic ulcers (UPU). If the anti-aggregatory effect were the sole mechanism involved, we would not expect an association between SSRIs and UPU. To our knowledge, such an association has not been investigated before. Material and methods
Setting
The data for this study were retrieved from three different sources, the Each prescription record includes a person identifier, the date of dispensing, the brand, quantity, and form of the drug. The substances and quantities are 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All these data were linked by using the mutual person identifier, the Central
Person Registry (CPR)-code, which is shared with virtually all other health related registries in Denmark, thereby allowing record-linkage studies.
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The study was approved by the Danish Data Protection Agency. An ethics committee approval was not required.
Cases and controls
• Cases (n=4862) were patients who had a diagnosis of UPU, either on an in-patient or an out-patient basis on one of the county's hospitals • Uncomplicated gastric ulcers: ICD8: 53191, 53193, 53194, 53196, 53198, 53199, ICD10: K25.3, K25.7 and K25.9.
• Others (anastomosis ulcers): ICD8: 53491, 53499, ICD10: K28.3, K28.7 and K28.9.
Cases were given an index date equivalent to the first registered date of an UPU diagnosis. Controls (n=19448) were matched for age-and sex and sampled by use of a risk set sampling technique. In brief, four controls for each case were randomly selected among those within the county who technique, the generated odd ratios will be unbiased estimates of the incidence rate ratios. 20 
Case validation
We performed a manual review of 500 clinical records randomly chosen among our cases. An UPU was defined as having a mucosal break that was We tested whether the non-valid cases were different from the valid cases with respect to their SSRI use and found no difference (p=0.69, chi-square)
Exposure definition
All the relevant SSRI doses are available on the Danish market as single tablets. We defined the exposure based on the assumption that the majority of patients would take one tablet per day. This assumption has been validated previously. 22 To allow for minor non-compliance and for irregular prescription refills, the exposure period were defined as days equivalent to the number of tablets in the dispensed package plus 20%. The exposure period started the day the prescription was redeemed, and the exposure clock was reset with each new prescription. "Recent exposure" was defined as the first 90 days after the expiry of an exposure period. The following period was defined as "past exposure". We undertook a sensitivity analysis with the grace period assigned to each prescription of 10%, 30% and 40% instead of the 20% used in the primary analysis. Results differed very little from the main analysis (data not shown).
Unless otherwise stated, analyses were based on current exposure, and the reference was person-time never-exposed to SSRI. "SSRI" refers to citalopram (N06AB04), escitalopram (N06AB10), fluoxetine (N06AB03), fluvoxamin (N06AB08), paroxetin (N06AB05) and sertraline (N06AB06).
Data analysis
The crude and adjusted ORs with 95% confidence intervals (CI), when relevant, were calculated by use of conditional logistic regression with adjustment for the potential confounders. Age, gender and calendar year were accounted by the study design.
A number of potential confounders were considered;
From FPAS, we retrieved information on the following diagnosis: previous gastric ulcer (ICD8-531; ICD10-K25), duodenal ulcer (ICD8-532; ICD10-K26), gastroduodenal ulcers (ICD8-533; ICD10-K27), gastritis and duodenitis (ICD8-535; ICD10-K29), a diagnosis of diabetes (ICD8-250, ICD10 E10-14), hypertension (ICD8-40, ICD10-I10), congestive heart 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and K28.4) and cirrhosis (ICD8 571; ICD10 K70.0-K70.9), as these were established risk factors for UPU.
The dose-response relationship was evaluated both in terms of daily dose taken and cumulative dose before the index date. To account for the difference in potency between SSRI, the Prescribed Daily Dose (PDD) was expressed in units of defined daily doses. 18 Intervals were defined by ≤0.5 DDD/day, 0.5-1.0 DDD/day and ≥1.0 DDD/day.
We defined the index date for the cases as being equivalent to the first registered date of an UPU diagnosis. An UPU could have been present a longer period before the endoscopy was performed. We performed a sensitivity analysis by redefining our index date to occur one and two months before the endoscopy, respectively.
The risk associated with current use of SSRI was expressed in absolute terms by using the NNTH principle ("the number of patients needed to be treated for one additional patient to be harmed"). 24 The adjusted odds ratios (OR) and the incidence of UPU in the background population unexposed to SSRI and aged 18 or above (ER unexp ) were used. NNTH is calculated by the formula; NNTH = 1/(ER unexp ×(OR − 1)). 24 We chose to exclude persons 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 person years. NNTH were calculated to 2300 person years (95% CI 1300-6400).
Discussion
In this large case-control study, patients with current use of SSRI had a moderate risk of being diagnosed with UPU. The increasing OR suggests a dose-response effect and a particularly high risk if the SSRI treatment is newly started. We found no association with current use of TCAs. Patients taking PPI appeared to be protected against SSRI-induced UPU.
The current study has several strengths. It is a true population-based study which has full coverage of admission and prescription data. Secondly we have manually validated approximately 10% of the case material. Thirdly;
with the current data we are able to account for a large number of covariates that are potential confounders.
Among the sources of error, we need to consider information bias, selection bias and residual confounding by variables that are not accounted for. 23 . It is unlikely that the validity of a UPU diagnosis would depend on whether the subject was an SSRI user. Thereby, the inclusion of non-valid cases is a non-differential misclassification bias which would tend to dilute the ORs towards unity. 26 In other words, the true OR without this bias would have been higher. We have performed a crude sensitivity analysis 27 which showed the OR to be fairly robust over a reasonable range of assumed validity for the diagnoses (data not shown).
It is conceivable that the frequent physician contact entailed in having depression or being treated with SSRIs would lead to endoscopy referral for ulcer-related complaints that would otherwise not come to medical attention.
This could generate a spurious SSRI-UPU association. A Norwegian study has showed that if an endoscopy is performed among healthy people, 7.4 % of the males and 4.6 of the women had peptic ulcers. 21 We attempted to address this "frequent physician contact" bias by analysing the association between anti-hypertensive drugs and UPU, as these drugs were thought to entail frequent physician contact as well. As with any observational study, residual confounding is a possibility. Table   1 shows that cases and controls differ substantially in their prevalence of traits that are risk factors or proxies for risk factors for UPU. As they should in an observational study. However, these risk factors will only bias our estimates to the extent that they are unevenly distributed between users and non-users of SSRIs. In our adjustment, we have included all variables that could be demonstrated as having a small confounding effect, and we have added the known strong risk factors for UPU. We believe it is unlikely that there is strong confounding by variables that have been registered.
However, the use of a registry-based approach renders our study vulnerable to potential confounders that are not covered by our databases; alcohol, smoking, and use of ulcerogenic over-the-counter (OTC) drugs. Users of SSRI smoke more than others 28 , but smoking is by itself only a modest risk factor for UPUs. 29 In addition, our estimates were not altered by the inclusion and exclusion of COPD in our model, i.e., a crude proxy for heavy smoking (OR 1.50 vs 1.49). Thus smoking is unlikely to confound our findings substantially. The studies we have been able to locate on alcohol and UPU report no association. 30,31 Alcohol abuse is a risk factor for bleeding ulcers but the risk is low with moderate to low intake. 32 We found a SSRI- High and low dose ASA and some NSAIDs are sold over the counter (OTC), which is not covered by our prescription database. To account for OTC sales, we compared the quantity registered in our database with the available data on total sales. The estimated coverage of our database for high dose ASA, low dose (<= 150 mg) ASA and NSAIDs was 4%, 90.5% and 84.3%, respectively. The gross sales volume of high-dose ASA was low, compared to low-dose ASA and NSAID; 11.0, 65.3 and 37.9 defined daily doses per 1000 inhabitants per day. 33 Although our prescription database thus has captured the major part of ulcerogenic drug use, we cannot exclude some residual confounding.
We also need to consider the indication for SSRIs as a source of confounding. To our knowledge, there is no known association between depression per se and UPU. In addition, we found no increased risk among users of tricyclic antidepressants, which have different pharmacological actions but are largely used for the same indications.
Could our results reflect a direct ulcerative effect by SSRI or is it mediated by its well known effect on the platelets? We have not been able to find any 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 37 Finally, we found a higher OR for paroxetine than for the other SSRIs. The reason for this is unknown. Paroxetine has a very high affinity among the SSRIs examined in this study and this could be the reason for the magnitude of the OR that we find. 38 However, it should be mentioned that this was not a pre-specified hypothesis, and it should be corroborated by others before any inferences can be made.
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